Sanofi and Regeneron report positive Phase 2 results of alirocumab Sanofi (SNY) and Regeneron (REGN) announced that nine new Phase 3 Odyssey trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol at 24 weeks compared to placebo or active comparator. In the nine trials, the mean percent reduction in LDL-C from baseline at 24 weeks in alirocumab-treated patients was consistent with results seen in previous alirocumab trials. A lower rate of adjudicated major cardiovascular events was observed in the alirocumab arm compared to placebo in a post-hoc analysis. The potential of alirocumab to demonstrate cardiovascular benefit is being prospectively assessed in an ongoing 18,000-patient Odyssey Outcomes trial. Alirocumab was generally well tolerated in the 9 trials.